Leadership change at Novo Nordisk
Danish pharma giant Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to revive sales and a share price hit by concerns that the Wegovy maker is falling behind in the weight-loss drug race it initiated.
The appointment comes after the abrupt removal in May of CEO Lars Fruergaard Jorgensen by Novo and the Novo Nordisk Foundation – the Danish company's controlling shareholder – and follows a growth warning earlier on Tuesday.
Doustdar, who joined Novo in 1992, currently serves as vice president for international operations, a role he assumed after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said.
The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the U.S., the largest market by far for weight-loss drugs and where they are most profitable.
Novo launched its weight-loss drug Wegovy nearly two and a half years before U.S. rival Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week.
The appointment comes at a challenging time for the global pharmaceutical industry as U.S. President Donald Trump threatens to impose tariffs on imports and calls on drugmakers to lower their U.S. prescription prices.
Jorgensen led Novo through a period of meteoric growth as it led the weight-loss drug boom, becoming Europe's most valuable listed company following the launch of Wegovy in 2021. At its peak in June 2024, Novo was worth as much as $615 billion.
But Novo shares have plunged since then due to investors' concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market, such as the threat to its sales from compounded copies of Wegovy and Lilly's Zepbound.
On Tuesday, the company also reduced its full-year sales and operating profit forecasts for the second time this year, causing its shares to decline as much as 17%.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Qatar Tribune
5 days ago
- Qatar Tribune
Leadership change at Novo Nordisk
Agencies Danish pharma giant Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to revive sales and a share price hit by concerns that the Wegovy maker is falling behind in the weight-loss drug race it initiated. The appointment comes after the abrupt removal in May of CEO Lars Fruergaard Jorgensen by Novo and the Novo Nordisk Foundation – the Danish company's controlling shareholder – and follows a growth warning earlier on Tuesday. Doustdar, who joined Novo in 1992, currently serves as vice president for international operations, a role he assumed after leading the company's businesses first in the Middle East and then in Southeast Asia, Novo said. The new chief executive's most urgent challenge, according to investors and analysts, is to revive Novo's performance in the U.S., the largest market by far for weight-loss drugs and where they are most profitable. Novo launched its weight-loss drug Wegovy nearly two and a half years before U.S. rival Eli Lilly's Zepbound. But Zepbound prescriptions surpassed those of Wegovy this year by more than 100,000 a week. The appointment comes at a challenging time for the global pharmaceutical industry as U.S. President Donald Trump threatens to impose tariffs on imports and calls on drugmakers to lower their U.S. prescription prices. Jorgensen led Novo through a period of meteoric growth as it led the weight-loss drug boom, becoming Europe's most valuable listed company following the launch of Wegovy in 2021. At its peak in June 2024, Novo was worth as much as $615 billion. But Novo shares have plunged since then due to investors' concerns about the company's experimental drug pipeline and its ability to navigate challenges in the U.S. market, such as the threat to its sales from compounded copies of Wegovy and Lilly's Zepbound. On Tuesday, the company also reduced its full-year sales and operating profit forecasts for the second time this year, causing its shares to decline as much as 17%.
Al Jazeera
23-06-2025
- Al Jazeera
Shipping giant Maersk divests from companies linked to Israeli settlements
Maersk will cut ties with companies linked to illegal Israeli settlements on the occupied West Bank, the Danish shipping giant has said. The decision follows months-long pressure by activists on Maersk on issues related to Palestine. Its shipments have come under scrutiny as part of an international campaign led by the Palestinian Youth Movement (PYM), a grassroots organisation. The group has focused mainly on Maersk's shipments of US foreign military sales, but PYM has also researched the transport of cargo from companies tied to settlements. A statement on the Maersk website, dated June, 2025, said, 'Following a recent review of transports related to the West Bank, we further strengthened our screening procedures in relation to Israeli settlements, including aligning our screening process with the OHCHR database of enterprises involved in activities in the settlements.' The Office of the United Nations High Commissioner for Human Rights (OHCHR) database includes businesses involved in various activities related to the settlements, such as providing services, equipment, or financial operations that support the illegal settlements. When asked for further details on its decision, Maersk pointed Al Jazeera to the statement on its website. It is unclear which or how many businesses Maersk had links to. Israel has built more than 100 settlements across the occupied West Bank that are home to some 500,000 settlers. These settlements, illegal under international law, range from small outposts to larger communities with modern infrastructure. 'This sends a clear message to the global shipping industry: compliance with international law and basic human rights is not optional. Doing business with Israel's illegal settlements is no longer viable, and the world is watching to see who follows next,' said PYM's Aisha Nizar. But she called for further action, arguing that Maersk still transports goods for the Israeli military, including components of its F-35 fighter planes. 'Maersk continues to profit from the genocide of our people – regularly shipping F-35 components used to bomb and massacre Palestinians,' Nizar said. 'We will continue to build pressure and mobilise people power until Maersk cuts all ties to genocide and ends the transport of weapons and weapons components to Israel.' Last year, Spain banned Maersk ships transporting military goods to Israel from using its ports. Earlier this month, PYM revealed how Maersk was using the port of Rotterdam as an essential link in what it called a 'supply chain of death'. Despite a Dutch court ruling that prohibited the Netherlands from exporting F-35 parts to Israel, Rotterdam still played a role in Israel's F-35 programme, the report showed. In response to those findings, Maersk told Al Jazeera that it upholds a strict policy of not shipping weapons or ammunition to active conflict zones and that it conducts due diligence, particularly in regions affected by active conflicts, including Israel and Gaza, and adapts this due diligence to the changing context. It confirmed, however, that its US subsidiary, Maersk Line Limited, was one of 'many companies supporting the global F-35 supply chain' with transport services.
Al Jazeera
16-05-2025
- Al Jazeera
In surprise move Wegovy-maker Novo Nordisk ousts CEO amid sagging sales
Wegovy-maker Novo Nordisk has pushed out CEO Lars Fruergaard Jorgensen over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market. Novo Nordisk announced the decision on Friday. Days earlier, Novo Nordisk cut its sales and profit forecast for the first time since the launch of Wegovy four years ago, though Jorgensen had predicted a return to growth in its biggest market in the second half of this year. Novo's chairman, Helge Lund, tried to reassure analysts and investors on a call that the company's strategy was intact and the plan for executing it had not changed. He told the Reuters news agency that discussions to replace Jorgensen had occurred over the past few weeks. Novo said earlier that Jorgensen will remain in his role until a successor is found. Under Jorgensen's leadership, Novo Nordisk became a world leader in the weight-loss drug market, with skyrocketing sales of its Wegovy and Ozempic treatments. Analysts and investors were unconvinced of the need to replace him. 'He was leading the company for eight years and was, in my opinion, extremely successful,' Lukas Leu, a portfolio manager at Bellevue Asset Management, told Reuters. Danske Bank analyst Carsten Lonborg Madsen was similarly caught off guard. 'The way we know Novo Nordisk is that normally you have patience when you're on the right track, and then you let things move in the right direction once you have the strategy right,' he said. 'It just feels like there's something that has gone pretty wrong here,' he said on the call. Novo's shares have plunged since hitting a record high in June last year as competition, particularly from US rival Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has failed to impress investors. 'The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024,' Novo said in its statement. Jorgensen, at 58, has been CEO since 2017. He said in an interview with Danish broadcaster TV2 that he did not see the decision coming, and was only informed very recently. Booming sales of Wegovy helped make Novo the most valuable listed company in Europe, worth $615bn at its peak in June last year, but its market value has halved to about $310bn. Novo Nordisk's share price fell on the news, trading 0.8 percent lower by 14:01 GMT after being 4 percent higher earlier in the day. The shares are down 32 percent year-to-date and 59 percent from their all-time high. Eli Lilly has seen US prescriptions for its Zepbound obesity shot surpass Wegovy since mid-March in its biggest market. Eli Lilly shares were up 2.6 percent after the news. Camilla Sylvest, Novo's head of commercial strategy and corporate affairs and a consistent presence alongside CEO Jorgensen, stepped down last month without citing a reason. Former CEO of Novo Nordisk for 16 years and current chair of the Novo Nordisk Foundation, Lars Rebien Sorensen, will join the board as an observer with immediate effect with the aim of taking a seat at the next annual general meeting, Novo said. The company is controlled by the Novo Nordisk Foundation through its investment arm, which owns 77 percent of the voting shares.
